Faculty Opinions recommendation of A randomized evaluation of the SAPIEN XT transcatheter heart valve system in patients with aortic stenosis who are not candidates for surgery.

Author(s):  
Nawwar Al-Attar
2015 ◽  
Vol 8 (14) ◽  
pp. 1797-1806 ◽  
Author(s):  
John G. Webb ◽  
Darshan Doshi ◽  
Michael J. Mack ◽  
Raj Makkar ◽  
Craig R. Smith ◽  
...  

2017 ◽  
Vol 65 (S 01) ◽  
pp. S1-S110
Author(s):  
F. Deuschl ◽  
N. Schofer ◽  
M. Seiffert ◽  
S. Hakmi ◽  
I. Mizote ◽  
...  

2021 ◽  
Vol 17 (1) ◽  
pp. 73-80 ◽  
Author(s):  
Samin K Sharma ◽  
Ravinder S Rao ◽  
Manik Chopra ◽  
Anmol Sonawane ◽  
John Jose ◽  
...  

The transcatheter aortic valve replacement (TAVR) is an established treatment for patients with severe symptomatic aortic stenosis (AS) at prohibitive risk for surgery. It is an alternative treatment to surgical aortic valve replacement in patients with AS at intermediate- and high-surgical risk. Although regulatory authorities extend the indications of TAVR to treat patients at low-surgical risk, the limitations of earlier-generation transcatheter heart valve (THV) systems accelerate the development of improved newer generation of THV systems. Myval™ THV (Meril Life Sciences Pvt. Ltd., Vapi, Gujarat, India) is a newer-generation, balloon-expandable TAVR system with features that facilitate accurate positioning of the bioprosthetic valve and favorable procedural and clinical outcomes. This review summarizes existing preclinical and clinical data on Myval THV for the intervention of symptomatic native AS and lays out the plan for future research program.


Author(s):  
Mario García‐Gómez ◽  
Jose Raúl Delgado‐Arana ◽  
Jonathan Halim ◽  
Federico De Marco ◽  
Carlo Trani ◽  
...  

2019 ◽  
Vol 14 (13) ◽  
pp. 1378-1385 ◽  
Author(s):  
Sebastien Hascoet ◽  
Robert Dalla Pozza ◽  
Jamie Bentham ◽  
Ronald Giacomo Carere ◽  
Majed Kanaan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document